- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05570344
rTMS With and Without Text4Support for the Treatment of Resistant Depression.
Repetitive Transcranial Magnetic Stimulation With and Without Text4Support for the Treatment of Resistant Depression: Patient-centered Multicentral Randomized Controlled Pilot Trial. Protocol.
Study Overview
Status
Conditions
Detailed Description
Objective: This study aims to assess the initial comparative clinical effectiveness of rTMS with and without the Text4Support program as an innovative patient-centered intervention for the management of participants diagnosed with TRD.
Methods: This study is a multicentered prospective, parallel-design, two-arm, rater-blinded randomized controlled pilot trial. The recruitment process is scheduled to last 12 months. It will involve active treatment for six weeks, observation, and a follow-up period of six months for participants in both arms of the study. In total, 200 participants diagnosed with TRD at rTMS care clinics in Edmonton, Alberta, and rTMS clinics in Halifax, Nova Scotia will be randomized to one of two treatment arms (rTMS sessions alone and rTMS sessions plus Text4Support intervention. Participants in each group will be made to complete evaluation measures at baseline, one month, three months, and six months. The primary outcome measure will be the mean change to scores on the Patient Health Questionnaire (PHQ-9). Patient service utilization data and clinician-rated measures will also be used to gauge patient progress. Patient data will be analyzed with descriptive statistics, repeated measures, and correlational analyses.
Interventions: Study participants will be randomized to one of the treatment interventions (rTMS alone or rTMS plus Text4Support). During the introductory visit to the study sites, participants in both arms of the study will be given a detailed orientation about the rTMS application, and all procedures and activities within each visit will be explained to them. As part of their participation in the rTMS program, all patients will be made to complete some standard measures. Participants will be invited to the various rTMS clinics a week before the commencement of the rTMS sessions to enable them to undergo motor threshold (MT) assessments. The MT assessment is essential in that it aids in the selection of the required stimulation intensity for each patient for inclusion in the treatment. MT assessment is a measure of the minimum intensity of TMS output needed to elicit a motor response in the participating TRD patients in at least 50% of all attempts.
The MT assessments will be conducted by the rTMS team of experts within the rTMS clinics in the various treatment centers and may consist of psychiatrists, nurses, and other healthcare professionals with the requisite knowledge to do so. Each TMS assessment session will take about 3-5 minutes, and the total time will be within 35-45 minutes. This visit timeline will be the same for all study participants. Overall, all study participants will be scheduled to receive 30 sessions of rTMS treatment for 6 weeks as pre-established by the Alberta Health Services Strategic Clinical Network for Addiction and Mental Health and Nova Scotia Health.
Additionally, participants in the rTMS plus Text4Support group of the study will be assisted by a study team member assigned that purpose to register on to the Text4Support program. The process will require all participants in this arm of the study to input their phone numbers into the Text4Support platform that will be used to deliver the daily messages. Starting a day after enrollment, participants will receive daily supportive text messages designed by mental health therapists, clinical psychologists, psychiatrists, and mental health service users. These messages are based on cognitive behavior therapy principles crafted to enhance positively the mood of its users with depressive symptoms and other related mental health problems of concern. The messages will be pre-programmed into a software program that will deliver the messages to participants automatically to the participants' mobile phones at 10 AM (Mountain Time) and 12 PM (Atlantic Time), and each participant will receive these messages continuously for 6 weeks.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Vincent Agyapong, MD, Ph.D
- Phone Number: 780-215-7771
- Email: agyapong@ualberta.ca
Study Contact Backup
- Name: Medard K Adu, BEd, MSc
- Phone Number: 5879376733
- Email: medard@ualberta.ca
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6R 3P5
- Recruiting
- Edmonton Mental Health Clinic
-
Contact:
- Vincent Israel O Agyapong, PhD
- Phone Number: 17807144315
- Email: agyapong@ualberta.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2E2
- Recruiting
- Nova Scotia Health - Abbie J. Lane Memorial Building QEII Health Sciences Centre
-
Contact:
- Vincent Agyapong
- Email: vincent.agyapong@nshealth.ca
-
Principal Investigator:
- Vincente Agyapong
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- aged 18 and above and diagnosed with MDD based upon the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) and who have at least failed two or more standard antidepressant treatments during the current episode. Participants may be on psychotropic medications including antidepressants, antipsychotics, benzodiazepines, and anticonvulsants. They must have a good understanding of the English language. Must have access to a smartphone and be able to receive and read text messages. Must be willing to provide written informed consent upon acceptance into the study.
Exclusion Criteria:
- Patients below the age of 18.
- Having diagnosis such as the following conditions (current unless otherwise stated): A neurological disorder, including a history of seizures, having primary or secondary tumors in the central nervous system, cerebrovascular disease, stroke, cerebral aneurysm, movement disorder,
- Having a current psychotic disorder such as substance-induced psychosis, psychotic disorder due to a medical condition, or MDD with psychotic features at the time of screening
- Having a current personality disorder that may hinder the patient's participation in this research or may have the potential of affecting cognition and ability to fully participate in the study.
- Having a learning disability as per identified through medical history or by the investigator during the assessment process.
- Participants involved in any drug or device clinical trial within the last six weeks before the screening visit and/or involvement in another clinical trial for the duration of this study.
- Pregnant and breastfeeding women.
- Identification and/or the sudden appearance of any condition or instance from the mentioned above and based on the expertise of the investigators that have the potential to hinder the progress and completion and/or become a confounding factor on the outcome assessments.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Enrolment in rTMS sessions alone
All study participants will be scheduled to receive 30 sessions of rTMS treatment for 6 weeks as pre-established by the Alberta Health Services Strategic Clinical Network for Addiction and Mental Health and Nova Scotia Health.
|
rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp.
|
Experimental: Enrolment in rTMS sessions plus Text4Support
Participants in the rTMS plus Text4Support group of the study would be assisted by a study team member assigned that purpose to register onto the Text4Support program.
The process would require all participants to input their phone numbers into the Text4Support platform that will be used to deliver the daily messages.
Starting a day after enrollment, participants will receive daily supportive text messages designed by mental health therapists, clinical psychologists, psychiatrists, and mental health service users.
These messages are based on cognitive behavior therapy principles crafted to enhance positively the mood of its users with depressive symptoms and other related mental health problems of concern.
The messages will be pre-programmed into a software program that will deliver the messages to participants automatically to the participants' mobile phones at 10 AM (Mountain Time) and 12 PM (Atlantic Time), and each participant will receive these messages continuously for 6 weeks.
|
rTMS uses powerful (1.0-2.5 Tesla), focused magnetic field pulses to induce electrical currents in neural tissue noninvasively, via an inductor coil placed against the scalp. Text4Support: Text4Support is one of the ResilienceNHope suites of supportive text messaging programs delivered by the Global Psychological eHealth Foundation [80]. The program allows users to receive daily supportive text messages which have been written by a team of cognitive-behavioral therapists and mental health professionals in collaboration with users of mental health services. The aim of this Text4Support depression program is to enhance positively the mood of patients with clinical depression. The program operates through the use of positive reinforcement to correct distorted or negative thought patterns. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Patient Health Questionnaire (PHQ-9)
Time Frame: Baseline
|
With 9 items, the PHQ-9 is half the length of many other depression measures, has comparable sensitivity and specificity, and it's made up of the actual 9 criteria upon which the diagnosis of depressive disorders according to the DSM-IV is based.
This instrument has the potential to establish major depressive disorder diagnoses as well as grading the severity of depressive symptom
|
Baseline
|
The Patient Health Questionnaire (PHQ-9)
Time Frame: 1 month
|
With 9 items, the PHQ-9 is half the length of many other depression measures, has comparable sensitivity and specificity, and it's made up of the actual 9 criteria upon which the diagnosis of depressive disorders according to the DSM-IV is based.
This instrument has the potential to establish major depressive disorder diagnoses as well as grading the severity of depressive symptom
|
1 month
|
The Patient Health Questionnaire (PHQ-9)
Time Frame: 3 months
|
With 9 items, the PHQ-9 is half the length of many other depression measures, has comparable sensitivity and specificity, and it's made up of the actual 9 criteria upon which the diagnosis of depressive disorders according to the DSM-IV is based.
This instrument has the potential to establish major depressive disorder diagnoses as well as grading the severity of depressive symptom
|
3 months
|
The Patient Health Questionnaire (PHQ-9)
Time Frame: 6 months
|
With 9 items, the PHQ-9 is half the length of many other depression measures, has comparable sensitivity and specificity, and it's made up of the actual 9 criteria upon which the diagnosis of depressive disorders according to the DSM-IV is based.
This instrument has the potential to establish major depressive disorder diagnoses as well as grading the severity of depressive symptom
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Generalized Anxiety Disorders Scale (GAD-7)
Time Frame: Baseline
|
The GAD-7 scale is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day."
GAD-7 total score for the seven items ranges from 0 to 21. (0-4: minimal anxiety, 5-9: mild anxiety, 10-14: moderate anxiety, and 15-21: severe anxiety)
|
Baseline
|
Generalized Anxiety Disorders Scale (GAD-7)
Time Frame: 1 month
|
The GAD-7 scale is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day."
GAD-7 total score for the seven items ranges from 0 to 21. (0-4: minimal anxiety, 5-9: mild anxiety, 10-14: moderate anxiety, and 15-21: severe anxiety)
|
1 month
|
Generalized Anxiety Disorders Scale (GAD-7)
Time Frame: 3 months
|
The GAD-7 scale is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day."
GAD-7 total score for the seven items ranges from 0 to 21. (0-4: minimal anxiety, 5-9: mild anxiety, 10-14: moderate anxiety, and 15-21: severe anxiety)
|
3 months
|
Generalized Anxiety Disorders Scale (GAD-7)
Time Frame: 6 months
|
The GAD-7 scale is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day."
GAD-7 total score for the seven items ranges from 0 to 21. (0-4: minimal anxiety, 5-9: mild anxiety, 10-14: moderate anxiety, and 15-21: severe anxiety)
|
6 months
|
Columbia Suicide Severity Rating Scale
Time Frame: Baseline
|
To assess suicidal ideation as symptom variable.
Suicidal Ideation Score: The maximum suicidal ideation category (1-5 on the C- SSRS) present at the assessment.
Assign a score of 0 if no ideation is present.
|
Baseline
|
Columbia Suicide Severity Rating Scale
Time Frame: 1 month
|
To assess suicidal ideation as symptom variable.
Suicidal Ideation Score: The maximum suicidal ideation category (1-5 on the C- SSRS) present at the assessment.
Assign a score of 0 if no ideation is present.
|
1 month
|
Columbia Suicide Severity Rating Scale
Time Frame: 3 months
|
To assess suicidal ideation as symptom variable.
Suicidal Ideation Score: The maximum suicidal ideation category (1-5 on the C- SSRS) present at the assessment.
Assign a score of 0 if no ideation is present.
|
3 months
|
Columbia Suicide Severity Rating Scale
Time Frame: 6 months
|
To assess suicidal ideation as symptom variable.
Suicidal Ideation Score: The maximum suicidal ideation category (1-5 on the C- SSRS) present at the assessment.
Assign a score of 0 if no ideation is present.
|
6 months
|
The World Health Organization - Five Well-Being Index (WHO-5)
Time Frame: Baseline
|
To assess the mental wellbeing as a functional variable.
The total raw score, ranging from 0 to 25, is multiplied by 4 to give the final score, with 0 representing the worst imaginable well-being and 100 representing the best imaginable well-being.
|
Baseline
|
The World Health Organization - Five Well-Being Index (WHO-5)
Time Frame: 1 month
|
To assess the mental wellbeing as a functional variable.
The total raw score, ranging from 0 to 25, is multiplied by 4 to give the final score, with 0 representing the worst imaginable well-being and 100 representing the best imaginable well-being.
|
1 month
|
The World Health Organization - Five Well-Being Index (WHO-5)
Time Frame: 3 months
|
To assess the mental wellbeing as a functional variable.
The total raw score, ranging from 0 to 25, is multiplied by 4 to give the final score, with 0 representing the worst imaginable well-being and 100 representing the best imaginable well-being.
|
3 months
|
The World Health Organization - Five Well-Being Index (WHO-5)
Time Frame: 6 months
|
To assess the mental wellbeing as a functional variable.
The total raw score, ranging from 0 to 25, is multiplied by 4 to give the final score, with 0 representing the worst imaginable well-being and 100 representing the best imaginable well-being.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vincent Agyapong, MD, Ph.D, Division of Community Psychiatry, University of Alberta
Publications and helpful links
General Publications
- Agyapong VIO, Juhas M, Ohinmaa A, Omeje J, Mrklas K, Suen VYM, Dursun SM, Greenshaw AJ. Randomized controlled pilot trial of supportive text messages for patients with depression. BMC Psychiatry. 2017 Aug 2;17(1):286. doi: 10.1186/s12888-017-1448-2.
- Agyapong VI, Mrklas K, Juhas M, Omeje J, Ohinmaa A, Dursun SM, Greenshaw AJ. Cross-sectional survey evaluating Text4Mood: mobile health program to reduce psychological treatment gap in mental healthcare in Alberta through daily supportive text messages. BMC Psychiatry. 2016 Nov 8;16(1):378. doi: 10.1186/s12888-016-1104-2.
- Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003 Sep 1;54(5):573-83. doi: 10.1016/s0006-3223(02)01866-8. Erratum In: Biol Psychiatry. 2003 Sep 1;54(5):585.
- Agyapong VI, Milnes J, McLoughlin DM, Farren CK. Perception of patients with alcohol use disorder and comorbid depression about the usefulness of supportive text messages. Technol Health Care. 2013;21(1):31-9. doi: 10.3233/THC-120707.
- Tanner JA, Hensel J, Davies PE, Brown LC, Dechairo BM, Mulsant BH. Economic Burden of Depression and Associated Resource Use in Manitoba, Canada. Can J Psychiatry. 2020 May;65(5):338-346. doi: 10.1177/0706743719895342. Epub 2019 Dec 13.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00122696
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Treatment-Resistant
-
Wayne Goodman MDActive, not recruitingTreatment Resistant Major Depressive DisorderUnited States
-
Taipei Veterans General Hospital, TaiwanRecruitingMajor Depressive Disorder | Treatment-resistant DepressionTaiwan
-
Taipei Veterans General Hospital, TaiwanRecruitingMajor Depressive Disorder | Treatment-resistant DepressionTaiwan
-
National Institute of Mental Health (NIMH)Taisho Pharmaceutical Co., Ltd.RecruitingDepression | Major Depressive Disorder | Treatment-Resistant DepressionUnited States
-
Medical University of GdanskPerception NeuroscienceEnrolling by invitationMajor Depressive Disorder | Treatment-Resistant DepressionPoland
-
Mclean HospitalMassachusetts General Hospital; PfizerTerminatedTreatment-Resistant DepressionUnited States
-
University of GreifswaldGerman Research Foundation; Charite University, Berlin, Germany; Hannover Medical... and other collaboratorsRecruitingTreatment-resistant Depression | Persistent Depressive DisorderGermany
-
University Health Network, TorontoCentre for Addiction and Mental HealthRecruitingDepression | Mood Disorders | Major Depressive Disorder | Treatment-Resistant DepressionCanada
-
Paul J. LamotheUnknownTreatment-Resistant Depression | Depressive Disorder,Mexico
-
Entheon Biomedical Corp.CompletedTreatment-resistant DepressionUnited States
Clinical Trials on Repetitive Transcranial Magnetic Stimulation (rTMS)
-
Centre Hospitalier Universitaire de NiceCompletedPost-traumatic Stress DisorderFrance
-
MGH Institute of Health ProfessionsNational Institute on Deafness and Other Communication Disorders (NIDCD)Recruiting
-
Centre hospitalier de Ville-Evrard, FranceRecruiting
-
Krystal Parker, PhDRecruitingDepression | Schizophrenia | Parkinson Disease | Bipolar Disorder | Autism Spectrum DisorderUnited States
-
Brigham and Women's HospitalBeth Israel Deaconess Medical Center; Mclean HospitalNot yet recruitingObesity | Appetitive BehaviorUnited States
-
Yi YangNot yet recruiting
-
Mclean HospitalNational Institute of Mental Health (NIMH); Beth Israel Deaconess Medical CenterRecruitingSchizophrenia | Schizo Affective DisorderUnited States
-
Tehran University of Medical SciencesUnknownBorderline Personality Disorder
-
Kaohsiung Veterans General Hospital.RecruitingBipolar II Disorder, Most Recent Episode Major DepressiveTaiwan
-
University of ManitobaCompleted